| Literature DB >> 22675290 |
Orly Lazarov1, Michael P Demars.
Abstract
Recent intriguing evidence suggests that metabolites of amyloid precursor protein (APP), mutated in familial forms of Alzheimer's disease (AD), play critical roles in developmental and postnatal neurogenesis. Of note is soluble APPα (sAPPα) that regulates neural progenitor cell proliferation. The APP family encompasses a group of ubiquitously expressed and evolutionarily conserved, type I transmembrane glycoproteins, whose functions have yet to be fully elucidated. APP can undergo proteolytic cleavage by mutually exclusive pathways. The subtle structural differences between metabolites generated in the different pathways, as well as their equilibrium, may be crucial for neuronal function. The implications of this new body of evidence are significant. Miscleavage of APP would readily impact developmental and postnatal neurogenesis, which might contribute to cognitive deficits characterizing Alzheimer's disease. This review will discuss the implications of the role of the APP family in neurogenesis for neuronal development, cognitive function, and brain disorders that compromise learning and memory, such as AD.Entities:
Keywords: Alzheimer’s disease; aging; amyloid precursor protein; learning and memory; neurogenesis; neuronal plasticity
Year: 2012 PMID: 22675290 PMCID: PMC3366480 DOI: 10.3389/fnins.2012.00081
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Figure 1APP structure. APP contains many functional domains as illustrated. The three most abundant isoforms of APP are APP770, APP751, and the predominantly neuronal APP695. From the N-terminal region these domains include a heparin binding and growth factor like domain (HBD1/GFLD), a copper binding domain (CuBD), zinc binding domain (ZnBD), an acidic region (DE), Kunitz-type protease inhibitor domain (KPI; not present in APP695), a second heparin binding domain (HBD2), random coiled region (RC), and the amyloid beta domain (Aβ). The inset displays the human amyloid beta sequence in red along with the sites of APP cleavage by α-, β-, and γ-secretase.
Figure 2APP processing: similarities to Notch processing. Both APP and Notch receptor may undergo proteolytic cleavage by α-secretase. In the case of APP, this cleavage prevents the formation of beta-amyloid (Aβ) peptides, and induces the release of the p3 fragment and the retention of a membrane-tethered fragment [carboxyl-terminal fragments of APP (APP-CTFs)], that is a substrate of γ-secretase cleavage, yielding APP intracellular domain (AICD) fragments. In the alternative, amyloidogenic pathway, APP is cleaved by β-secretase prior to γ-secretase. In the case of the Notch receptor, the holoprotein is cleaved in the trans Golgi network by a furin-like protease activity in the juxtamembrane extracellular domain, giving rise to two fragments (120 and 180 kDa) that remain associated as a heterodimer. It is thought that Notch reaches the cell membrane in this assembly, where it can undergo activation by ligand binding, following which it gets cleaved by α-secretase to yield the “Notch extracellular truncated” derivative (NEXT). Similarly to the APP-CTFs, only this truncated derivative is then cleaved by γ-secretase. Similarly to NICD, AICD fragments are thought to translocate to the nucleus and activate gene transcription.
Physiological roles of sAPP.
| Citation | Metabolite | Suggested role | Developmental stage and type of cell/tissue source | Methodology | Observations |
|---|---|---|---|---|---|
| Hung et al. ( | Full length APP | Neuronal differentiation | P19 murine embryonic carcinoma cells. Primary hippocampal neurons E18 rat embryos. | Retinoic acid-induced neuronal differentiation. Northern blot analysis. | Increased APP transcript upon cell differentiation. In correlation with neurofilament. |
| Salbaum and Ruddle ( | APP | Neuronal differentiation | Mouse embryo tissue. | Immunohistochemistry | APP is expressed in subset of differentiated neurons. Correlation of APP expression in MAP2. |
| Rossjohn et al. ( | sAPP | Growth factor-like structure | Crystals of the proteolytic-breakdown product, residues 23–128 of APP derived from a construct, consisting of residues 18–350 from the APP1-770 isoform, that was expressed and purified from | The N′-terminus of APP has a growth factor-like structure. | |
| Saitoh et al. ( | sAPP | Fibroblast proliferation | SV40-transformed human fetal lung fibroblasts IMR-90-SV40 (AG2604) and 293 human embryonic kidney cell line overexpressing APP or transfected with antisense. | Cell growth, antisense, sAPP containing conditioned media, Northern blot analysis, Western blot. | Cell growth is sAPP-dependent. |
| Pietrzik et al. ( | sAPP | Proliferation factor of thyroid cells | FRTL-5 rat thyroid follicle cells. | Antisense, recombinant sAPP, cell growth, immunohistochemistry, immunoprecipitation. | sAPP stimulates phosphorylation mediated by mitogen-activated protein kinase and evokes proliferation in thyroid epithelial cell line FRTL-5 in the presence of TSH. |
| Hoffmann et al. ( | sAPP | Proliferation of keratinocytes (epidermal basal cells) | Human skin, human skin cell line HaCaT. | Immunohistochemical detection of APP in skin in conjunction with β1-integrin, PCR and biochemical detection of APP in skin cells. BrdU proliferation assay and cell count for proliferation. APP antisense effect on HaCaT. | APP is expressed in human skin, mainly in the epidermis. APP751 and 770 are the predominant isoforms expressed in HaCaT. |
| APP antisense reduced proliferation of HaCaT by 50% | |||||
| Ohsawa et al. ( | sAPP | Proliferation factor of embryonic neural stem cells | E13 neocortical rat cells | BrdU pulse cell labeling for proliferation | sAPP enhances the proliferation of embryonic neural stem cells. |
| Ko et al. ( | APP and sAPP | Upregulation of APP and sAPP enhances OSCC proliferation | Oral squamous cell carcinoma (OSCC) cell line and tissue | Cell growth RT-PCR and Western blot analysis for APP transcript | Increase in APP mRNA and protein expression in OSCC relative to corresponding non-cancerous cells. APP751 and APP770 are the major APP isoforms in oral keratinocytes. OSCC tissue. Treatment with an antisense oligonucleotide against APP reduced cellular and secreted APP as well as growth in an OSCC cell line. |
| Takayama et al. ( | APP and sAPP | APP and sAPP regulate androgen-dependent prostate cancer cell proliferation. | Human prostate cancer LNCaP cells. | ChIP combined with genome tiling array analysis (ChIPchip) using DNA of prostate cancer cell. APP immunoreactivity in LNCaP cells. Proliferation assay for extent of growth of LNCaP. | APP expression is regulated by androgen and is androgen-inducible in LNCaP cells. |
| Caille et al. ( | sAPP | Regulates proliferation of NPC in the adult SVZ. | Adult mice and SVZ neurosphere cultures. Brain tissue of 2-month-old Swiss mice. | Continuous infusion of sAPP for 3 days into the lateral ventricle of adult mice. BrdU injected intraperitoneally (1 mg in 100 ml) 1 h before perfusion. BrdU, EGFR staining. | The SVZ is a major sAPP binding site. |
| Demars et al. ( | sAPPα | Proliferation factor of NPC, MSC and human placenta stem cells. | Brain sections of adult mice, mouse SVZ neurosphere cultures, adult mouse MSC, and hdpPSC cultures. | Neurospheres treated with metalloproteinase broad-spectrum inhibitor and recombinant sAPPα. Neurosphere formation assay. Western blot and Immunohistochemistry of APP, nestin, sox2 + and ADAM10 in mouse brain sections. | sAPPα is a stand-alone proliferation factor of NPC in the adult SVZ, of adult MSC and hdpPSC. |
| Baratchi et al. ( | sAPP | Proliferation factor of adult NPC in the SGL and regulates astrocytic fate lineage regulator. | Adult rat SGL or SVZ neurosphere cultures. | Treatment of neurosphere culture with recombinant sAPPα and sAPPβ. BrdU intake proliferation assay 4 h BrdU pulse, harvest 12 h later. Differentiation assay and immunocytochemistry for MAP2, GFAP, and DAPI, calbindin. | sAPPα and sAPPβ increased the proliferation of SGZ-derived NPC. Treatment of SGZ-derived NPC with either sAPPα and sAPPβ increased the number of cells expressing GFAP and promoted cell survival. |
| Rohe et al. ( | sAPPα and sAPPβ | sAPP are SORLA-regulated proliferation and survival factors of adult neurogenesis. | Wild-type and SORLA-deficient mice. | 5- and 14-month old wild-type and SORLA-deficient mice. Quantification of BrdU incorporation in the SGL 24 h post pulse. DCX immunostaining for early neuronal differentiation. Survival of BrdU+ cells in the SGL 4 weeks post pulse. | Increased cell proliferation in the SGL of SORLA-deficient animals compared with wild-type controls. No change in neuronal differentiation. Increased survival of BrdU-positive cells. |
| Katakowski et al. ( | sAPPα | TACE-cleaved sAPPα regulates NPC proliferation in the SVZ following stroke | Adult rats | MCAO in adult male rats. Seven days post-MCAO, NPC were isolated from the SVZ ipsilateral to infarct. | Upregulation of APP and TACE-induced sAPP production in NPC in the SVZ following MCAO. Greater extent of TACE-promoted NPC proliferation in the SVZ following MCAO. |
| Goodman and Mattson ( | sAPP695 and sAPP751 | Neuroprotectant | E18 rat embryo hippocampus | Synthetic Aβ or reversed peptide. sAPP expressed in 293 Human kidney cells either sAPP695 or sAPP751. Hippocampal neuronal cultures from E18 rat embryos. | sAPP695 or sAPP751 protects hippocampal neurons from Aβ toxicity, that involves secretion of free radicals and calcium imbalance. |
| Neuronal survival by light microscopy. | |||||
| Thornton et al. ( | sAPPα | sAPPα is a neuroprotectant of TBI with anti-apoptotic characteristics. | Adult rats | Adult male Sprague-Dawley rats underwent impact–acceleration of diffuse traumatic brain injury. Vehicle or sAPPα were stereotaxically injected into the lateral ventricle right after TBI. | Intracerebroventricular administration of sAPPα shortly after TBI improved motor outcome (rotarod), and reduced number of apoptotic neurons in CA3 and cortex 3 days post TBI based on immunoreactivity for caspase-3. |
| Masliah et al. ( | Human APP | Human APP is a neuroprotectant of chronic and acute excitotoxicity. | C57BL/6xSJL; NSE–hAPP transgenic mice. | Transgenic lines expressing human APP isoforms in neurons treated with systemic kainate injections or transgene-mediated glial expression of gp120 for excitotoxic neuronal damage. Area of neuropil occupied by presynaptic terminals and neuronal dendrites in the neocortex and hippocampus was determined using confocal microscopy of immunolabeled brain section. GFAP for astroglia and F4/80 for microglial. | Based on the area of the neuropil occupied by immunolabeled dendrites and presynaptic terminals, mice from three human APP751/gp120 bigenic lines showed significant protection against degeneration of presynaptic terminals; two of these lines also showed significantly less damage to neuronal dendrites. Two of three human APP695/gp120 bigenic lines expressing human APP695 were protected against presynaptic and dendritic damage. |
| Gralle et al. ( | APP and sAPPα | APP is a receptor for sAPPα. sAPPα neuroprotects cells by inhibiting APP dimerization. | Neuroblastoma cells | Single molecule tracking using quantum dots and quantitated APP homodimerization using fluorescence lifetime imaging microscopy. | Dimerization of APP takes place primarily at the plasma membrane. Dimerization of APP is heparan sulfate-dependent. APP is s receptor for sAPPα, and sAPPα binding disrupts APP dimers, leading to the protection of neuroblastoma cells from cell death. |
| Wehner et al. ( | sAPPα | sAPPα exerts a pronounced cytoprotective effect mediated by facilitated cell adhesion. | HaCaT cells and normal human keratinocyte (NHK) cultures. | Apoptosis induction in HaCaT cells and normal human keratinocytes (NHK) culture following elimination of fetal calf serum and bovine pituitary extract. | Recombinant sAPPα protects keratinocytes from apoptosis by facilitating the substrate adhesion of keratinocytes and promoting binding to keratinocytes. Recombinant sAPPα inhibits apoptosis n HaCaT cells following moderate UV-B irradiation and staurosporine-induced apoptosis. In contrast, induction of apoptosis in NHK required additionally the depletion of endogenous sAPPα. |
| Sugaya ( | sAPPα | sAPPα promotes glial differentiation. | Human NPCs | HNPCs treated with recombinant sAPPα following Staurosporine treatment. APP treatment increased CNTF, gp130, JAK1, Delta, Hes1, BMP4 and GFAP. | sAPPα induced expression of CNTF, gp130 JAK1, Notch intracellular domain and Hes1 as well as STAT3 phosphorylation. Silencing these genes by RNA interference suppressed the glial differentiation. |
| Kwak et al. ( | sAPPα | sAPPα promotes glial differentiation via Notch. | APP23 mice, human NPC | Transplantation of human NPCs in APP23 and wild-type mice. Treatment of human NPC and NT-2/D1 cells with sAPP | NPC transplanted into APP23 transgenic mice differentiated into glia. Treatment of human NPC and NT-2/D1 with sAPP increased the number of GFAP positive cells and enhanced the generation of NICD and Hes1. Treatment with γ-secretase inhibitor suppressed the generation of NICD and reduced Hes1 and GFAP expression. Treatment with the N-terminal domain of APP (APP 1–205) induced upregulation of GFAP and Hes1 expressions, while 22C11 antibodies abolished these changes. |
| Chen et al. ( | sAPP | sAPP promotes MSC neuronal differentiation | Bone marrow-derived adult progenitor cells (MAPC) | Treatment of bone marrow-derived adult progenitor cells with sAPP and assessment of differentiation by immunocytochemistry. Transplantation of sAPP-induced MAPC intravenously. | Addition of sAPP to NGF/RA-stimulated MAPC induced extension of processes, immature synaptic complexes and increased expression of neuronal proteins including NeuN, β-tubulin-III, NFM, and synaptophysin, compared to MAPC differentiated by NGF/RA. Cells exhibited an increase in the levels of choline acetyltransferase, MAPC were detected within the septohippocampal system of APP/PS1 mice injected intravenously with sAPPα-transfected MAPC. |
| Freude et al. ( | Wild-type APP, FAD-mutant APP, sAPPα or sAPPβ | Wild-type APP, FAD-mutant APP, sAPPα, or sAPPβ promote differentiation into NPC. | WA09 (H9) hESC and HUES7 hESC | hESC infected with lentiviral vectors overexpressing APP wild-type or Swedish mutant, or treated with recombinant sAPPα or β express NPC markers nestin, sox2, TUJ-1, GFAP. | APP overexpression or sAPPα or sAPPβ induced differentiation of hESC toward a neural fate (nestin and β –III tubulin expression). |
| Kirfel et al. ( | sAPP | sAPP is a motogen of keratinocytes, with chemoattractant and chemokinetic effects. | Human epidermal keratinocytes from neonatal skin. | Migration assay of keratinocytes recorded by video microscopy, lamella dynamics and migration velocity. Path length and the directional persistence of cell migration was analyzed by β1-integrin migration track assay. PAK1-coupled agarose beads was used for the precipitation of PAK1/Rac complexes. | sAPP-induced an increase in the proportion of polarized cells and in lamella and ruffle dynamics. sAPP increased proportion of migrating keratinocytes and migration velocity to a similar extent to EGF. Stimulating effect of sAPP on lamellipodia and ruffle frequencies was blocked by inhibition of tyrosine kinase with genistein. sAPP-induced activation of Rac kinase. |
| Young-Pearse et al. ( | APP, C′ and N′ terminus | APP regulates the migration of embryonic cortical NPC. | Rat embryonic cortex | Electroporation of shRNA constructs targeting APP wild-type, metabolites and derivatives into the developing cortex. Immunohistochemical analysis using the following markers: anti-APP 22C11, MAP2, NeuN, anti-APLP1, anti-APLP2, GFAP, nestin, Tbr1, Oct6. | NPC in embryonic cortex require APP for migration into the nascent cortical plate. knockdown of APP inhibited cortical plate entry, and overexpression of APP caused accelerated migration of cells past the cortical plate. cDNAs encoding human APP or APLP1,2, fully rescued migration defect following APP knockdown. Both the extracellular and cytoplasmic domains of APP are required for efficient rescue. Dab1 acts downstream of APP in cortical plate entry. |
| Ohsawa et al. ( | sAPPα, specifically the amino terminus of sAPPα. | sAPPα enhances neurite outgrowth and neuronal survival in embryonic neurons. | Rat embryonic neocortical explants | Recombinant APP695s (Met1-Lys612 of human APP695), recombinant NAPP (Arg16-Val290 of human770), recombinant CAPP (Glu380-Thr663 of human APP770). Neurite outgrowth assay in rat neocortical explants following addition of recombinant proteins. Survival assay in neocortical neuronal culture. Quantification by phase microscopy. | The amino terminus of sAPP, but not the carboxyl terminus, enhanced neurite outgrowth and neuronal survival. Likewise, the 16-mer peptide of 22C11 enhanced neurite outgrowth and neuronal survival. |
| Qiu et al. ( | Cell surface APP | Cell surface APP enhances neuronal adhesion and outgrowth | Rat embryonic hippocampal neurons | APP-expressing CHO cells as the substratum of rat embryonic primary hippocampal neurons. Assessment of adhesion (minutes–hours after culturing cells) and neurite outgrowth by phase microscopy. | Neuronal adhesion and outgrowth was enhanced in the presence of APP-overexpressing CHO cells compared to non-transfected CHO cells. sAPP and Aβ failed to simulate this effect in the absence of enhanced cell surface-APP. APP751 and 770 isoforms promoted neuronal outgrowth better than the 695 isoform. The domain 361–648 of APP mediates growth-promoting effects. |
| Gakhar-Koppole et al. ( | sAPPα and sAPLP2 | Enhance neurite outgrowth in differentiating NPC. | NPCs from mouse striata, APLP2 single knockout, and APP /APLP2 KO embryos E14 or P7. | Differentiating NPC cultures were treated with differentiation medium, with or without sAPPα. For depolarization, differentiating NPC were treated with depolarizing medium (an increased K+ concentration of 50 mm). Quantification of neurite length by microscopy. | sAPPα is required for depolarization-induced neurite outgrowth in NPC. Treatment of differentiating NPC with recombinant sAPPα enhances neurite outgrowth. sAPLP2 but not sAPLP1 shows redundancy to sAPP in promoting neurite outgrowth. |
| Roch et al. ( | sAPPα 17-mer peptide | Enhances memory retention by regulating synaptic structure | Adult rat brain | Aged and young rats. 17-mer peptide of sAPP containing the sequence of amino acids 328–332 was infused into the lateral ventricle of rats for 2 weeks. Reversal learning and memory retention by Morris water-maze. Synapses by synaptophysin immunoreactivity in brain sections. | Infusion of APP 17-mer peptide increased the number of presynaptic terminals in the frontoparietal cortex and enhanced memory retention. |
| Bell et al. ( | sAPPα | sAPPα regulates presynaptic bouton density. | Adult mouse brain | Subcutaneous infusion of sAPPα into the neck and shoulder area of adult mice for 7 days. Examination of presynaptic bouton density in lamina V and VI of the F1/F2 cortical regions and in Lamina V and VI of the Parietal regions 1 and 2 or P1/P2. Immunohistochemical identification of presynaptic boutons by markers for VAChT (cholinergic), VGluT (glutamatergic), and GAD (GABAergic). | Infusion of sAPPα into the brains of adult mice induces an elevation in cortical cholinergic, glutamatergic and GABAergic presynaptic bouton density. |
A detailed summary of studies examining the physiological role(s) of sAPP in cell proliferation, migration, viability, and differentiation. ADAM10, A disintegrin and metalloproteinase domain-containing protein 10; APP, amyloid precursor protein; BACE1, beta-site APP cleaving enzyme 1 or β-secretase; BMP4, bone morphogenetic protein 4; BrdU, 5′-bromo-2′-deoxyuridine; ChIP, chromatin immunoprecipitation; CNTF, ciliary neurotrophic factor; DAB1, disabled-1; DAPI, 4′,6-diamidino-2-phenylindole; DCX, doublecortin; E18, embryonic day 18; EGF, epidermal growth factor; EGFR, EGF receptor; GAD, glutamic acid decarboxylase; GFAP, glial fibrillary acidic protein; hdpPSC, human placenta stem cells; hESC, human embryonic stem cells; JAK, Janus kinase; KGF, keratinocyte growth factor; MAPC, bone marrow-derived adult progenitor cells; MCAO, middle cerebral artery occlusion; MAP-2, microtubule-associated protein 2; MSC, mesenchymal stem cells; NFM, neurofilament; NGF, nerve growth factor; NHK, normal human keratinocyte; NPC, neural progenitor cells; NSE, neuron specific enolase; OSCC, oral squamous cell carcinoma; PAK1, serine/threonine-protein kinase; P19, postnatal day 19; PCR, polymerase chain reaction; RA, retinoic acid; RT-PCR, real time polymerase chain reaction; SGL, subgranular layer of the dentate gyrus; SORLA, sortilin-related receptor with A-type repeats; SOX2, SRY (sex determining region Y)-box 2; STAT3, signal transducer and activator of transcription; SVZ, subventricular zone; TACE, Tumor necrosis factor alpha converting enzyme; TAP1,2, tumor necrosis factor-a protease inhibitor-1,2; TBR1, T-box, brain, 1; TGFα, transforming growth factor α; TSH, thyrotropin; VAChT, vesicular acetylcholine transporter; VGluT, vesicular glutamate transporter.
Figure 3APP metabolites in neurogenesis. The formation of new neurons or astroglia in the adult brain is a multifaceted process including the necessity of a niche that supports continuous proliferation of neural progenitor cells, the determination of neural lineage, migration of immature cells often across large distances, and the functional incorporation into existing neural networks. Many of the metabolites of APP have been implicated in one or more of these processes. In order to fully understand the impact of APP metabolism on neurogenic processes, we must first unravel the individual functions of each of the metabolites in order to better realize the implications of alterations in the cleavage pattern of APP.
APP animal models and neurogenesis.
| Genetic manipulation | Reference | Genotype | Phenotype | Neurogenesis |
|---|---|---|---|---|
| Single knockout | Zheng et al. ( | APPKO | Viable and fertile; reduced brain weight; reactive gliosis; reduced locomotor activity and forelimb grip strength; reduced dendritic length, LTP and GABAergic post-synaptic currents; aging linked memory impairment. | Increased neurogenesis of NPC derived from APPKO E14 embryos |
| Heber et al. ( | APLP1KO | Viable and fertile; reduced body weight. | N/A | |
| von Koch et al. ( | APLP2KO | Viable and fertile; no major abnormalities. | N/A | |
| Double knockout | Heber et al. ( | APP/APLP1KO | Viable and fertile. | N/A |
| von Koch et al. ( | APP/APLP2KO | Postnatal lethality; defects at neuromuscular and interneuronal synapses; | N/A | |
| Heber et al. ( | APLP1/APLP2KO | Postnatal lethality; no gross abnormalities. | N/A | |
| Triple knockout | Herms et al. ( | APP/APLP1/APLP2KO | Postnatal lethality; lissencephaly; abnormal neuroblast migration. | Normal migration, polarity, and ability to form functional synapses in embryonic stem cells |
| Human APP overexpression | Rockenstein et al. ( | PDGF-APPWT | Viable and fertile; reduced presynaptic terminals. | Reduced NPC proliferation in the SGL; Increased NPC survival; impaired maturation to neural or glial fate |
| APP truncated mutant | Muller et al. ( | APP(Δ/Δ) | Viable and fertile; callosal agenesis; reduced brain weight; reduced locomotor activity; impaired swimming navigation; reduced motivation to avoid noxious stimulus; spatial learning deficits. | N/A |
| Truncated APP knock-in | Ring et al. ( | APPΔCT15-KI | Viable and fertile; rescues impairments associated with APPKO | N/A |
| sAPPα knock-in | Ring et al. ( | APPsα-KI | Viable and fertile; rescues impairments associated with APPKO. | Increased expression of neurogenesis-related genes. |
| APLP2 KO/sAPP knock-in | Li et al. ( | APPsβ-KI | Unable to rescue postnatal lethality of APP/APLP2KO; impaired neuromuscular synapses. | N/A |
| Weyer et al. ( | sAPPα-DM | Rescues postnatal lethality of APP/APLP2KO; impaired neuromuscular synapses; hippocampal dysfunction; impaired LTP; spatial learning deficits. | N/A | |
| APPKO/AICD | Ghosal et al. ( | FeCυ25;APP−/− | Viable and fertile; neuroinflamation. | Reduced Proliferation of hippocampal NPC; Reduced survival of NPC; differentiation – unaffected. |
| Conditional knockouts | Mallm et al. ( | APP(Δ/−) | Viable and fertile; reduced grip strength, brain, and body weight | N/A |
| Mallm et al. ( | APLP2(Δ/−) | Viable and fertile | N/A |
A list of the currently available mouse models to study APP and APP family members. The general phenotype of each is described in brief as well as a description of any work that has been done with respect to neurogenesis in each mouse model.